DAEWOONG PHARMACEUTICAL CO., LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 111,600 KRW | -0.62% |
|
+3.24% | -4.45% |
| Apr. 24 | Korean Sugar Imports Plunge 14% as Diabetes Cases Surge | MT |
| Apr. 12 | AEON Biopharma, Inc. announced that it has received $15 million in funding from Daewoong Pharmaceutical Co., Ltd | CI |
| Sales 2024 * | 1,296B 941M | Sales 2025 * | 1,399B 1.02B | Capitalization | 1,271B 923M |
|---|---|---|---|---|---|
| Net income 2024 * | 88B 63.89M | Net income 2025 * | 114B 82.76M | EV / Sales 2024 * | 1.2 x |
| Net Debt 2024 * | 278B 202M | Net Debt 2025 * | 236B 171M | EV / Sales 2025 * | 1.08 x |
| P/E ratio 2024 * |
14.5
x | P/E ratio 2025 * |
11.3
x | Employees | 1,679 |
| Yield 2024 * |
0.54% | Yield 2025 * |
0.54% | Free-Float | 37.6% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | -0.62% | ||
| 1 week | +3.24% | ||
| Current month | -8.00% | ||
| 1 month | -6.45% | ||
| 3 months | +0.72% | ||
| 6 months | +9.52% | ||
| Current year | -4.45% |
1 week
106 700.00
113 000.00
1 month
106 700.00126 900.00
Current year
106 700.00127 600.00
1 year
88 300.00127 600.00
3 years
88 300.00195 500.00
5 years
63 200.00286 500.00
10 years
54 500.00286 500.00
| Managers | Title | Age | Since |
|---|---|---|---|
Seung-Ho Jeon
CEO | Chief Executive Officer | 49 | 03-03-31 |
Chung-Woo Lee
AUD | Comptroller/Controller/Auditor | 58 | - |
Jin-Hwan Park
PRN | Corporate Officer/Principal | 56 | 02-09-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Hong-Cheol Kim
BRD | Director/Board Member | 53 | 18-03-22 |
Seung-Ho Jeon
CEO | Chief Executive Officer | 49 | 03-03-31 |
Dae-Duk Kim
BRD | Director/Board Member | 61 | 22-03-28 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 4 M€ | -4.41% | - | |
| 0.00% | 117 M€ | +0.68% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-24 | 111,600 | -0.62% | 8,895 |
| 24-04-23 | 112,300 | +1.35% | 12,844 |
| 24-04-22 | 110,800 | +3.07% | 12,718 |
| 24-04-19 | 107,500 | -1.56% | 16,839 |
| 24-04-18 | 109,200 | +1.02% | 15,335 |
End-of-day quote Korea S.E., April 23, 2024
More quotes
Daewoong Pharma is a Korea-based company principally engaged in the manufacture and distribution of pharmaceuticals. The Company's products mainly include antihypertensive drugs, antianemic agents, antidiabetic agents, antiemetic agents, antihistamine agents, antimicrobials, antineoplastics, antiobesity agents, antipyretic agents, analgesic agents, anti-inflammatory agents, biosimilars, remedies for bone and joint diseases, cardiovascular treatments, central nervous system treatments, digestive agents, dermatologic agents, gastrointestinal agents, health supplements and respiratory remedies, among others. The Company distributes its products in domestic and overseas markets.
Sector
Pharmaceuticals
Calendar
2024-05-12
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -4.45% | 933M | |
| +18.59% | 22.25B | |
| +14.45% | 14.39B | |
| +12.83% | 13.55B | |
| +38.02% | 11.27B | |
| -9.80% | 6.95B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +6.29% | 5.01B | |
| -8.24% | 4.51B |
- Stock Market
- Equities
- A069620 Stock
